Interleukin-18 in the pathogenesis of atherosclerosis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atherosclerosis is a chronic inflammatory disease of the cardiovascular system, which is one of the main causes of coronary heart disease, ischemic stroke, and peripheral vascular disease. Currently, there is growing evidence pointing to the importance of innate and adaptive immunity in the development of atherosclerosis. Interleukin-18 (IL-18) is one of the pro-inflammatory cytokines involved in the process of atherogenesis, destabilization of atherosclerotic plaques, and their rupture. This review examines the results of preclinical and clinical studies on the role and mechanism of action of IL-18 in the pathogenesis of atherosclerosis.

Full Text

Restricted Access

About the authors

A. M. Syrodoev

Lipetsk Regional Clinical Hospital

Author for correspondence.
Email: anton.syrodoev@mail.ru
SPIN-code: 3959-7235
Russian Federation, Lipetsk

E. Y. Esina

N.N. Burdenko Voronezh State Medical University, Ministry of Health of Russia

Email: anton.syrodoev@mail.ru
ORCID iD: 0000-0001-7048-9428
SPIN-code: 7732-7427

MD

Russian Federation, Voronezh

References

  1. Attaway A., Ayache M., Velani S. et al. Atherosclerosis: an inflammatory disease. Am J Resp Crit Care Med. 2017; 196 (7): 920–2. DOI: 10.1164/ rccm.201702-0428RR
  2. Шишкина Е.А., Хлынова О.В., Туев А.В. Возможности использования полиморфизма rs2070744 гена эндотелиальной синтазы оксида азота для идентификации тяжелого коронарного атеросклероза у больных инфарктом миокарда молодого и среднего возраста. Врач. 2020; 31 (9): 35–40 [Shishkina E.A., Khlynova O.V., Tuev A.V. Possibilities of using the rs2070744 polymorphism of the endothelial nitric oxide synthase gene for the identification of severe coronary atherosclerosis in young and middle-aged patients with myocardial infarction. Vrach. 2020; 31 (9): 35–40 (in Russ.)]. doi: 10.29296/25877305-2020-09-06
  3. Bahrami A., Sathyapalan T., Sahebkar A. The Role of Interleukin-18 in the Development and Progression of Atherosclerosis. Curr Med Chem. 2021; 28 (9): 1757–74. doi: 10.2174/0929867327666200427095830
  4. Гусев Е.Ю., Зотова Н.В., Журавлева Ю.А. и др. Физиологическая и патогенетическая роль рецепторов-мусорщиков у человека. Медицинская иммунология. 2020; 22 (1): 7–48 [Gusev E.Yu., Zotova N.V., Zhuravleva Yu.A., Chereshnev V.A. Physiological and pathogenic role of scavenger receptors in humans. Medical Immunology (Russia). 2020; 22 (1): 7–48 (in Russ.)]. doi: 10.15789/1563-0625-PAP-1893
  5. Кочергин Н.А., Кочергина А.М., Хорлампенко А.А. и др. Нестабильные атеросклеротические бляшки коронарных артерий при стабильной ишемической болезни сердца: 12-месячное наблюдение. Кардиология. 2020; 60 (2): 69–74 [Kochergin N.A., Kochergina A.M., Khorlampenko A.A. et al. Vulnerable atherosclerotic plaques of coronary arteries in patients with stable coronary artery disease: 12-months follow-up. Kardiologiia. 2020; 60 (2): 69–74 (in Russ.)]. doi: 10.18087/cardio.2020.2.n467
  6. Kaplanski G. Interleukin-18: Biological properties and role in disease pathogenesis. Immunol Rev. 2018; 281 (1): 138–53. doi: 10.1111/imr.12616
  7. Otsuka F., Yasuda S., Noguchi T. et al. Pathology of coronary atherosclerosis and thrombosis. Cardiovasc Diagn Ther. 2016; 6 (4): 396–408. doi: 10.21037/cdt.2016.06.01
  8. Formanowicz D., Gutowska K., Formanowicz P. Theoretical Studies on the Engagement of Interleukin 18 in the Immuno-Inflammatory Processes Underlying Atherosclerosis. Int J Mol Sci. 2018; 19 (11): 3476. doi: 10.3390/ijms19113476
  9. Martinez G.J., Celermajer D.S., Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018; 269: 262–71. doi: 10.1016/j.atherosclerosis.2017.12.027. [Erratum in: Atherosclerosis. 2018; 273: 157. doi: 10.1016/j.atherosclerosis.2018.03.043].
  10. Tang X. Analysis of interleukin-17 and interleukin-18 levels in animal models of atherosclerosis. Exp Ther Med. 2019; 18 (1): 517–22. doi: 10.3892/etm.2019.7634
  11. Wang J., Sun C., Gerdes N. et al. Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter. Nat Med. 2015; 21 (7): 820–6. doi: 10.1038/nm.3890
  12. Зыков М.В., Кашталап В.В., Быкова И.С. и др. Клиническое и прогностическое значение сывороточного интерлейкина-18 у больных инфарктом миокарда с подъемом сегмента ST. Российский кардиологический журнал. 2015; 11: 70–4 [Zykov M.V., Kashtalap V.V., Bykova I.S. et al. Clinical and predictive value of serum interleukine-18 in ST elevation myocardial infarction. Russian Journal of Cardiology. 2015; 11: 70–4 (in Russ.)]. doi: 10.15829/1560-4071-2015-11-70-74
  13. Xie S.-L., Chen Y.-Y., Zhang H.-F. et al. Interleukin 18 and extracellular matrix metalloproteinase inducer cross-regulation: implications in acute myocardial infarction. Transl Res. 2015; 165: 387–95. doi: 10.1016/j.trsl.2014.09.001
  14. Понасенко А.В., Цепокина А.В., Хуторная М.В. и др. Полиморфизм генов IL18RAP и IL18R1 ассоциирован с рисками развития инфаркта миокарда у пациентов со стабильной формой ишемической болезни сердца. Трансляционная медицина. 2018; 5 (4): 12–22 [Ponasenko A.V., Tsepokina A.V., Khutornaya M.V. et al. The polymorphism of IL18RAP and IL18R1 genes associated with risks of the development of myocardial infarction in patients with stable coronary artery disease. Translational Medicine. 2018; 5 (4): 12–22 (in Russ.)]. doi: 10.18705/2311-4495-2018-5-4-12-22
  15. Åkerblom A., James S.K., Lakic T.G. et al.; PLATO Investigators. Interleukin-18 in patients with acute coronary syndromes. Clin Cardiol. 2019; 42 (12): 1202–9. doi: 10.1002/clc.23274
  16. Коротаева А.А., Самойлова Е.В., Миндзаев Д.Р. и др. Провоспалительные цитокины при хронической сердечной недостаточности: состояние проблемы. Терапевтический архив. 2021; 93 (11): 1389–94 [Korotaeva A.A., Samoilova E.V., Mindzaev D.R. et al. Pro-inflammatory cytokines in chronic cardiac failure: state of problem. Terapevticheskii Arkhiv. 2021; 93 (11): 1389–94 (in Russ.)]. doi: 10.26442/00403660.2021.11.201170
  17. Jia X., Buckley L., Sun C. et al. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2023; 30 (16): 1731–40. doi: 10.1093/eurjpc/zwad197
  18. Martinez-Hervas S., Martinez-Barquero V., Nuñez Savall E. et al. Plasma IL-18 levels are related to insulin and are modulated by IL-18 gene polymorphisms. Clin Investig Arterioscler. 2015; 27 (6): 265–71. doi: 10.1016/j.arteri.2015.04.004
  19. Sun H., Zhang J., Zheng Y. et al. Expressions and clinical significance of factors related to acute coronary syndrome. J Biol Regul Homeost Agents. 2018; 32 (2): 299–305.
  20. Arapi B., Bayoğlu B., Cengiz M. et al. Increased Expression of Interleukin-18 mRNA is Associated with Carotid Artery Stenosis. Balkan Med J. 2018; 35 (3): 250–5. doi: 10.4274/balkanmedj.2017.0323
  21. Ridker P.M., MacFadyen J.G., Thuren T. et al. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur Heart J. 2020; 41 (23): 2153–63. doi: 10.1093/eurheartj/ehz542
  22. Hoseini F., Mahmazi S., Mahmoodi K. et al. Evaluation of the Role of -137G/C Single Nucleotide Polymorphism (rs187238) and Gene Expression Levels of the IL-18 in Patients with Coronary Artery Disease. Oman Med J. 2018; 33 (2): 118–25. doi: 10.5001/omj.2018.23
  23. Sadeghi M., Gheraati M., Soleimani A. et al. Serum interleukin-18 and extent of coronary artery disease in unstable angina. ARYA Atheroscler. 2018; 14 (3): 122–7. doi: 10.22122/arya.v14i3.1370
  24. Scherr C., Albuquerque D.C., Pozzan R. et al. Role of Interleukin-18 and the Thrombus Precursor Protein in Coronary Artery Disease. Arq Bras Cardiol. 2020; 114 (4): 692–8. doi: 10.36660/abc.20190176
  25. Дедов Д., Ковальчук А. Предуктал МВ в лечении и профилактике кардиоваскулярных осложнений у больных ИБС. Врач. 2013; 12: 40–1 [Dedov D., Kovalchuk A. Preductal MV in the treatment and prevention of cardiovascular complications in patients with coronary heart disease. Vrach. 2013; 12: 40–1 (in Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Russkiy Vrach Publishing House